Article Text

other Versions

PDF
Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconus
  1. David P S O'Brart1,
  2. Tsong Q Kwong1,
  3. Parul Patel1,
  4. Robert J McDonald1,
  5. Naomi A O'Brart2
  1. 1Department of Ophthalmology, Keratoconus Research Institute, St. Thomas’ Hospital, London, UK
  2. 2School of Optometry, University of Cardiff, Cardiff, Wales
  1. Correspondence to David P S O'Brart, Department of Ophthalmology, Keratoconus Research Insitute, St. Thomas’ Hospital, London SE1 7EH, UK; davidobrart{at}aol.com

Abstract

Aims To determine long-term efficacy of riboflavin/ultraviolet A corneal cross-linking (CXL).

Methods Thirty patients (30 eyes) who had undergone CXL following epithelial removal 4–6 years previously were examined.

Results At 1-year mean, spherical equivalent error (SEQ) increased by +0.72 dioptres (D) (p<0.002), corrected distance visual acuity (CDVA) improved (p<0.005), mean simulated keratometry (Sim K) reduced by 0.27D (p<0.04), cone apex power (CAP) reduced by 0.4D (p<0.02), and secondary astigmatism improved (p<0.03) compared with preoperative values. At 4–6 years, mean SEQ increased by +0.82D (p<0.001), CDVA improved (p<0.03), mean Sim K reduced by 0.84D (p<0.00001), CAP reduced by 1.16D (p<0.0005), and root mean square (RMS) (p<0.0001), coma (p<0.0001), secondary astigmatism (p<0.005) and pentafoil (p<0.05) decreased compared with preoperative values. At 4–6 years, mean Sim K reduced by 0.59D (p<0.0005), CAP reduced by 0.76D (p<0.02), RMS (p<0.001), coma (p<0.002) and secondary astigmatism (p<0.02) reduced and central pachymetry increased (p<0.05) compared with 1 year. No treated eyes progressed. None lost >1 line of CDVA. Seven untreated fellow eyes progressed.

Conclusions CXL is an effective and safe treatment with up to 4–6 years follow-up. Improvements in topographic and wave-front parameters evident at 1 year continue to improve at 4–6 years.

  • Cornea
  • Clinical Trial
  • Treatment Surgery

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.